Intelsat Introduces First-of-its-kind “FlexMove” Managed Service for Ubiquitous Land Mobile Connectivity
Intelsat (NYSE: I) today launched FlexMove, a new end-terminal managed service that makes it easy and affordable for people to connect to the Internet, private data networks and cloud services from virtually anywhere in the world, including while on-the-move, or on-the-pause at a temporary site. Businesses, first responders and humanitarian-aid organizations can now use this secure, reliable, “always-on” service to stay connected anywhere their jobs take them.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005607/en/
FlexMove is powered by Intelsat’s award-winning global Epic high-throughput satellite (HTS) fleet, the world’s largest fixed satellite network and the IntelsatOne ground network to provide users with a seamless global connectivity experience. (Graphic: Business Wire)
“Intelsat engineers and innovators are laser-focused on developing flexible, affordable managed services that help our customers connect and communicate seamlessly, no matter where their business may take them,” said Intelsat Senior Vice President for Mobility Mark Rasmussen. “Our new FlexMove service provides a breakthrough in speed, convenience and affordability, ultimately enabling more companies and organizations to operate with confidence in even the most remote or challenging locations.”
There are many remote locations around the globe that fiber and terrestrial wireless networks can’t reach, and where ground infrastructure is at risk of disruption by natural or man-made events. That’s where integrated connectivity solutions, like those from Intelsat, prove invaluable. FlexMove is powered by Intelsat’s award-winning global Epic high-throughput satellite (HTS) fleet, the world’s largest fixed satellite network and the IntelsatOne ground network to provide users with a seamless global connectivity experience.
Traditional Mobile Satellite Service (MSS) solutions come with a high price tag and don’t have the features or bandwidth necessary to power the data-intensive applications that end-users are increasingly demanding. FlexMove offers data rates 20 times faster than these traditional MSS solutions at a fraction of the cost per byte. As the only commercial satellite operator with an independent third-party Service Organization Control 3 (SOC 3) cybersecurity accreditation, end users can also rest assured that Intelsat’s space and ground network is secure.
Virtually anyone can set-up the FlexMove service and connect to the internet in minutes. FlexMove services for Communications-on-the-Move (COTM) applications use a flat-panel compact, vehicle-mounted satellite terminal that automatically acquires a connection and maintains communication while the vehicle is moving. The Communications-on-the-Pause (COTP) service uses a highly compact and portable satellite terminal with an automatic or assisted pointing function to connect to a satellite. Connectivity choices include a public Internet connection or a private IP solution to access a customer’s network.
Intelsat FlexMove service packages offer pre-set data rates sold by the gigabyte (GB) and can be used on qualified terminals available through a global network of solution partners, including Intelsat’s FlexMove launch partner GRC .
“GRC are delighted to be selected as an Intelsat FlexMove partner and as a testament to the services, features and cost-effective gigabyte plans, we've already got customers signed up from both the Defense and Government sectors,” said GRC Managing Director Steve Slater. “We anticipate FlexMove will continue to grow over the coming months, and combined with our single case secure comms SCYTALE and SATCUBE package, the capability is a game changer for the rapid notice-to-move deployments common to Defense and First Response users, or anyone looking for an easy to operate, high-bandwidth satellite solution.”
Intelsat’s easy-to-use service portal enables FlexMove solution partners to provision, configure and quickly monitor network access in real-time through an online interface or integrated APIs.
FlexMove-qualified terminals are manufactured and supplied by Kymeta, for COTM applications, and by Satcube and Starwin, for COTP applications.
Potential solution partners, technology developers and end-users interested in the FlexMove service can visit www.intelsat.com/land-mobile and click “Contact Us.”
About Intelsat:
As the foundational architects of satellite technology, Intelsat operates the world’s largest and most advanced satellite fleet and connectivity infrastructure. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is uniquely positioned to help our customers turn possibilities into reality – transformation happens when businesses, governments and communities use Intelsat’s next-generation global network and managed services to build their connected future. Imagine Here, with us, at Intelsat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005607/en/
Contact information
Media Contact:
Meghan Macdonald
meghan.macdonald@intelsat.com; (703) 559-7372
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom